|
radiotherapy |
5 |
|
breast cancer |
4 |
|
lymphopenia |
4 |
|
brain metastasis |
3 |
|
deep learning |
3 |
|
immune biomarkers |
3 |
|
immunotherapy |
3 |
|
low-dose volume |
3 |
|
lung cancer |
3 |
|
non-small cell lung cancer |
3 |
|
non-small-cell lung cancer |
3 |
|
prediction model |
3 |
|
radiotherapy (rt) |
3 |
|
systemic tumor immune environment |
3 |
|
tumor immune microenvironment |
3 |
|
conditional survival |
2 |
|
cytokine |
2 |
|
functional imaging |
2 |
|
lung dosimetric factors |
2 |
|
overall survival |
2 |
|
radiation esophagitis |
2 |
|
radiation-induced lung fibrosis |
2 |
|
sabr |
2 |
|
sbrt |
2 |
|
single-cell transcriptomics |
2 |
|
support vector machine |
2 |
|
systemic tumor immune environment (stie) |
2 |
|
tumor immune microenvironment (time) |
2 |
|
18f-rgd |
1 |
|
4d-mri |
1 |
|
4dct |
1 |
|
5d-mri |
1 |
|
ablative radiation |
1 |
|
adverse events |
1 |
|
antiangiogenic |
1 |
|
bladder volume |
1 |
|
brachytherapy |
1 |
|
brain metastases |
1 |
|
cervical cancer |
1 |
|
constrained lasso |
1 |
|
contouring |
1 |
|
ct |
1 |
|
deformable image registration |
1 |
|
dosimetric parameters |
1 |
|
effective dose to the circulating immune cells (edic) |
1 |
|
efficacy toxicity trade-off |
1 |
|
film dosimetry |
1 |
|
gene mutation |
1 |
|
grid therapy |
1 |
|
immune checkpoint inhibitors |
1 |
|
immune organ at risk |
1 |
|
immune system |
1 |
|
immune-response |
1 |
|
integrin αvβ3 |
1 |
|
intensity modulated radiotherapy (imrt) |
1 |
|
limited-stage small-cell lung cancer (sclc) |
1 |
|
lung |
1 |
|
lung metastasis |
1 |
|
lymphocyte count |
1 |
|
metastasis |
1 |
|
mr-guided radiotherapy |
1 |
|
multi-contrast mri |
1 |
|
nomogram |
1 |
|
oligometastases |
1 |
|
optimal treatment regime |
1 |
|
overall survival (os) |
1 |
|
pancoast tumor |
1 |
|
personalized medicine |
1 |
|
pet/ct |
1 |
|
platelet-to-lymphocyte ratio |
1 |
|
pneumonitis |
1 |
|
predictive model |
1 |
|
predictor |
1 |
|
prognosis |
1 |
|
qa |
1 |
|
quality assurance |
1 |
|
radiation |
1 |
|
radiation dose to the blood |
1 |
|
radiation pneumonitis (rp) |
1 |
|
radiation-induced immune toxicity |
1 |
|
radiomics |
1 |
|
radiosensitivity |
1 |
|
radiotherapy dose |
1 |
|
re-irradiation |
1 |
|
resection |
1 |
|
soluble programmed death ligand 1 |
1 |
|
spatially fractionated radiotherapy |
1 |
|
stereotactic ablative body radiotherapy (sabr) |
1 |
|
stereotactic body ablative radiotherapy |
1 |
|
stereotactic body radiation therapy |
1 |
|
stereotactic body radiation therapy (sbrt) |
1 |
|
stereotactic body radiotherapy |
1 |
|
stereotactic radiosurgery |
1 |
|
survival |
1 |
|
target volumes |
1 |
|
thoracic |
1 |
|
toxicity |
1 |
|
tumor-enhanced contrast |
1 |
|
utility |
1 |
|
ventilation |
1 |
